Singapore markets close in 6 hours 45 minutes

Lyell Immunopharma, Inc. (LYEL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.1100-0.0900 (-2.14%)
At close: 04:00PM EDT
3.9800 -0.13 (-3.16%)
After hours: 04:05PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.01B
Enterprise value 465.18M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)115.17
Price/book (mrq)1.15
Enterprise value/revenue 53.11
Enterprise value/EBITDA -2.19

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-75.67%
S&P500 52-week change 3-5.29%
52-week high 319.8400
52-week low 33.5700
50-day moving average 35.0730
200-day moving average 39.0162

Share statistics

Avg vol (3-month) 31.3M
Avg vol (10-day) 31.01M
Shares outstanding 5246.14M
Implied shares outstanding 6N/A
Float 8131.31M
% held by insiders 115.88%
% held by institutions 159.09%
Shares short (12 May 2022) 415.18M
Short ratio (12 May 2022) 424.73
Short % of float (12 May 2022) 48.90%
Short % of shares outstanding (12 May 2022) 46.17%
Shares short (prior month 13 Apr 2022) 416.63M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin 0.00%
Operating margin (ttm)-2,584.93%

Management effectiveness

Return on assets (ttm)-14.52%
Return on equity (ttm)-33.80%

Income statement

Revenue (ttm)8.76M
Revenue per share (ttm)0.05
Quarterly revenue growth (yoy)-77.40%
Gross profit (ttm)10.65M
EBITDA -210.54M
Net income avi to common (ttm)-263.32M
Diluted EPS (ttm)-1.3670
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)613.91M
Total cash per share (mrq)2.49
Total debt (mrq)68.81M
Total debt/equity (mrq)7.81
Current ratio (mrq)15.24
Book value per share (mrq)3.59

Cash flow statement

Operating cash flow (ttm)-140.5M
Levered free cash flow (ttm)-131.68M